bioRxivBioinformaticsPreprint
Analysis of single-cell RNA-seq data from ovarian cancer samples before and after chemotherapy links stress-related transcriptional profile withchemotherapy resistance
Kaiyang ZhangiD, Erdoğan Pekcan ErkaniD, Jun DaiiD, Noora AnderssoniD, Katja KaipioiD, Tarja LammineniD, Naziha MansuriiD, Kaisa HuhtineniD, Olli CarpéniD, Johanna HynnineniD, Sakari HietaneniD, Jaana OikkoneniD, Antti HäkkineniD, Sampsa HautaniemiiD, Anna VähärautioiD
Abstract
Chemotherapy resistance is the greatest contributor to cancer mortality and the most urgent unmet challenge in oncology. In order to reveal transcriptomics changes due to platinum-based chemotherapy we analyzed single-cell RNA-seq data from fresh tissue samples taken at the time of diagnosis and after neoadjuvant chemotherapy from 11 high-grade serous ovarian cancer (HGSOC) patients. With a novel clustering method accounting for patient-specific variability and technical confounders, we identified 12 clusters. Of these, a stress-related transcriptional profile was enriched during chemotherapy and associated significantly to poor progression-free survival (PFS) and disease-free interval (DFI) in deconvoluted bulk RNA-seq data analysis of treatment-naive samples in TCGA cohort. Pan-cancer cell line analysis suggests that patients with high stress-related transcriptional profile may benefit from MEK1/2 inhibitors instead of platinum. Further, high proportion of stromal components and high interaction score between tumor and stromal suggest the tumor cells with high-stress profile actively interact with and potentially recruit stromal cells to their microenvironment already prior to chemotherapy, potentially facilitating protection from chemotherapeutic treatments. In summary, we have identified a stress-related transcriptional profile, which is present at the time of diagnosis, enriched during platinum treatment, independent predictor for poor PFS and DFI, and, based on in vitro data, targetable with MEK1/2 inhibitors. Translational relevanceWe discovered a stress-related transcriptional profile that is significantly enriched in fresh tissue samples after chemotherapy and is significantly associated with poor progression-free survival in an independent patient cohort. The survival association is independent of age, tumor purity or BRCAness. Therefore, this chemotherapy resistance associated profile is intrinsic and could thus be targeted already in treatment-naive patients. The translation potential of the stress-related transcriptomics profile was further supported by pan-cancer cell line analysis that showed that cell lines with high stress-related transcriptional profile are not affected by platinum, corroborating our results, whereas they were more sensitive to MEK1/2 inhibitors. Taken together, the stress-related transcriptional profile, quantifiable with a set of 35 marker genes, provides a basis for improved prediction of platinum response as well as novel avenues to treat this patient group more effectively.
- Citations
- 2
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Novel regulatory and transcriptional networks associated with resistance to platinum-based chemotherapy in ovarian cancer
D. G. Topouza, J. Choi, … Q. L. Duan·bioRxiv·Sep 9, 2020
- Secreted soluble factors from tumor-activated mesenchymal stromal cells confer platinum chemoresistance to ovarian cancer cells
Y. Koren Carmi, R. Adawi, … J. Mahajna·bioRxiv·Feb 24, 2023
- Protein Expression Patterns in ovarian cancer cells Associated with Monofunctional Platinums Treatment
L. Arzuman, M. A. Moni, … F. Huq·bioRxiv·May 7, 2019
- Gene networks and expression quantitative trait loci associated with platinum-based chemotherapy response in high-grade serous ovarian cancer
J. Choi, A. Tarnouskaya, … Q. Duan·bioRxiv·Nov 26, 2019
- Single-Cell Transcriptomic Signatures Enable Stratified Combination Therapy for Platinum-Resistant Ovarian Cancer
Laura Gall-Mas, Katrin Kleinmanns, … Benno Schwikowski·bioRxiv·Mar 6, 2026
- The capacity of the ovarian cancer tumor microenvironment to integrate inflammation signaling conveys a shorter disease-free interval
K. R. Jordan, M. J. Sikora, … B. G. Bitler·Clinical Cancer ResearchPeer-reviewed·Dec 1, 2020